{
    "symbol": "VKTX",
    "quarter": 3,
    "year": 2022,
    "date": "2022-10-26 22:50:27",
    "content": " The increase was primarily due to increased expenses related to legal services, stock-based compensation and salaries and benefits. The increase was primarily due to increased expenses related to manufacturing for the company's drug candidates, salaries and benefits and stock-based compensation, partially offset by decreased expenses related to the company's clinical studies, preclinical studies and third-party consultants. The increase was primarily due to increased expenses related to manufacturing for the company's drug candidates, salaries and benefits and stock-based compensation, partially offset by decreased expenses related to the company's clinical studies, preclinical studies and third-party consultants. The increase was primarily due to increased expenses related to legal services, stock-based compensation and salaries and benefits."
}